Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 4/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 4/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 4/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308058 | 0.88 | DGAT1 (0.62) | DYRK1ADGAT1CSGALNACT1LCKMAPT | |
| SCHEMBL2307313 | 0.86 | NPC1 (0.60) | DYRK1AMAPTNPC1KDM4EMEN1 | |
| SCHEMBL1748046 | 0.85 | NPC1 (0.53) | DYRK1ADGAT1CSGALNACT1MAPTNPC1 | |
| SCHEMBL2308930 | 0.85 | MAPT (0.58) | PPARAMAPTNPC1SENP7KDM4E | |
| SCHEMBL2307188 | 0.85 | DYRK1A (0.52) | DYRK1ADGAT1CSGALNACT1MAPTNPC1 | |
| SCHEMBL1761323 | 0.84 | DGAT1 (0.52) | DYRK1AFSCN1DGAT1CSGALNACT1PPARA | |
| SCHEMBL2308352 | 0.83 | DYRK1A (0.60) | DYRK1AFSCN1DGAT1CSGALNACT1LCK | |
| SCHEMBL14881026 | 0.82 | DGAT1 (0.45) | DYRK1AFSCN1DGAT1CSGALNACT1PPARA | |
| SCHEMBL1748025 | 0.81 | DGAT1 (0.49) | DYRK1AFSCN1DGAT1CSGALNACT1PPARA | |
| SCHEMBL2307254 | 0.80 | NPC1 (0.50) | DYRK1APPARAMAPTNPC1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | claimed |
| EP-1633722-B1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2011-08-03 | — | — | EP | claimed |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER | 2009-10-29 | — | — | US | claimed |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2009-08-06 | — | — | US | claimed |
| US-7423156-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | claimed |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | claimed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | claimed |
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| EP-1633722-B1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2011-08-03 | — | — | EP | disclosed |
| EP-1633722-B1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2011-08-03 | — | — | EP | disclosed |
| US-7968576-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER A | 2011-06-28 | — | — | US | disclosed |
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | SMITH ROGER | 2009-10-08 | — | — | US | disclosed |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2009-08-06 | — | — | US | disclosed |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2009-08-06 | — | — | US | disclosed |
| US-7423156-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423156-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-7091228-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | DYRK1A 3333/4885FSCN1 4689/4885DGAT1 34/4885 |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | DYRK1A 3333/4885FSCN1 4689/4885DGAT1 34/4885 |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | DYRK1A 3333/4885FSCN1 4689/4885DGAT1 34/4885 |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | DYRK1A 3333/4885FSCN1 4689/4885DGAT1 34/4885 |
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | DYRK1A 3333/4885FSCN1 4689/4885DGAT1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.